B Cell Depleting Therapy for Multiple Sclerosis Overlapping with Neuromyelitis Optica Spectrum Disorder

Lu, T.T., Shu, Y.Q., Dai, Y.Q., Liu, X., Chang, Y.Y., Huang, Q., Kermode, A. and Qui, W. (2018) B Cell Depleting Therapy for Multiple Sclerosis Overlapping with Neuromyelitis Optica Spectrum Disorder. Multiple Sclerosis Journal, 24 (3). p. 420.

Abstract

Background: Multiple sclerosis and neuromyelitis optica spectrum disorder and are currently thought to be independent entities. Some patients display intermediate manifestations that fit the criteria for both diseases without positive relevant serobiomarkers. An overall standard and consensus for the diagnosis and treatment of these overlapping patients have not been reached.

Objective: The aim of this study was to explore potential proper treatments for these patients.

Methods: We describe a patient with frequently relapsing demyelinating episodes and repeatedly adjusted treatment regimens due to diagnostic difficulties.

Results: The case was not well responsive to glucocorticoid plus azathioprine, or interferon. Benefits were obtained by using rituximab, a B cell scavenger targets humoral immunity.

Conclusions: Treatments targeting B cell mediated humoral immunity may be a safe and appropriate choice for the challenging demyelinating cases, especially in Asian population.

Item Type:	Journal Article
Murdoch Affiliation(s):	Institute for Immunology and Infectious Diseases
Publisher:	Sage Publications
Copyright:	© 2018 by SAGE Publications
Other Information:	Poster presentation PACTRIMs 2017
URI:	http://researchrepository.murdoch.edu.au/id/eprint/40817

Item Control Page